anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Active Duodenal Ulcer. The recommended adult oral dosage for duodenal ulcer is 1 g (10 mL) four times per day. Sucralfate Oral Suspension should be administered on an empty stomach. 

Antacids may be prescribed as needed for relief of pain but should not be taken within one-half hour before or after Sucralfate Oral Suspension. 

While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination.

Elderly. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy (see PRECAUTIONS Geriatric Use). 

Call your doctor for medical advice about side effects. You may report side effects to Amneal Pharmaceuticals at 1-877-835-5472 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
The embodiments herein provides a method for synthesis of non-bitter herbal composition comprising  Bacopa monnieri  extracts. The method comprises the following steps. The dried  Bacopa monnieri  herb is grinded with a pulverizer. The herb powder is 5 mixed with 80% v/v alcohol. The aqueous alcohol extract is obtained in a soxhlet apparatus. The herbal extract is subjected to acid hydrolysis with 20% v/v HCl. The alcohol fraction is removed from the herbal extract after acid hydrolysis. The  Bacopa monnieri  herbal extract is cooled at room temperature to obtain a precipitate. The precipitate is washed with de-mineralized water. The precipitate is extracted or washed with three volumes of ethyl acetate at 65 °C thrice. The ethyl acetate fractions are concentrated. The concentrated ethyl acetate fraction is dried at 65°C under vacuum. The herbal extract is administered to the people in the form of capsules/tablets and in foods and beverages.
UNLABELLED: Aberrant long noncoding RNAs just proximal to Xist (lncRNA JPX) expression levels have been detected in multiple tumors. However, whether JPX is involved in melanoma progression remains unclear. Our study showed that JPX expression is significantly increased in melanoma tissues and cell lines. To clarify the effect of JPX on cutaneous melanoma, we successfully generated JPX-overexpressing or JPX-knockdown A375 and A2058 cells. CCK-8, colony formation EdU, Transwell, and cell-cycle phase assays were performed, and subcutaneously implanted tumor models were used to determine the function of JPX in cutaneous melanoma. The results showed that JPX knockdown reduced the proliferation and migration of malignant melanoma cells both in vitro and in vivo. To further elucidate the molecular mechanism of JPX-induced cutaneous melanoma deterioration, we performed RNA pull-down, RNA immunoprecipitation, coimmunoprecipitation, Western blot, and RNA-sequence analyses. JPX can directly interact with YTHDF2 and impede the protection of YTHDF2 from ubiquitin-specific protease 10 (USP10), which promotes its deubiquitination. Thus, JPX decreases protein stability and promotes the degradation of YTHDF2, thereby stabilizing BMP2 mRNA and activating AKT phosphorylation. Overall, our study revealed a novel effect of JPX on YTHDF2 ubiquitination, suggesting the possibility of blocking the JPX/USP10/YTHDF2/BMP2 axis as a prospective therapeutic approach for cutaneous melanoma.
IMPLICATIONS: This study highlights the ubiquitination effect of USP10 and JPX on YTHDF2 in cutaneous melanoma, and proposes that the JPX/USP10/YTHDF2/BMP2 axis may be a prospective therapeutic target for cutaneous melanoma.
This study was conducted as a randomized controlled study to determine the effect of fixing the peripheral intravenous catheter (PIVC) with additional circular dressing material on the duration of stay of the peripheral intravenous catheter and complications related to peripheral intravenous catheterization. In our study, a comparison was made of PIVCs applied to patients in the control (fixation of PIVC with a sterile transparent dressing) and intervention (fixation of PIVC with a sterile transparent dressing and application of an elastane circular dressing on it) groups in a public hospital in Turkey. In our study, PIVC failure was defined as PIVC removal before the end of treatment due to phlebitis, infiltration, accidental dislodgement, occlusion, and leakage. A total of 91 (47 intervention, 44 control) participants were included in the study between April 2023 and September 2023. All-cause PIVC failure was significantly higher in the intervention group (70.2%) compared to the control group (45.5%). It was determined that fixing the PIVC with additional circular dressing material prolongs the duration of PIVC stay at the site. It is recommended that this study be conducted with a different patient population and multicenter.
This is an open-label (all people know the identity of the intervention), multicenter (when more than one hospital or medical school team work on a medical research study) study of ICZ in participants with onychomycosis. The present study consists of 2 periods: Screening period (up to Week minus 2) and Treatment period (up to Week 49). The ICZ will be administered in 3 cycles (Week 1, Week 5 and Week 9) and each cycle will consist of taking 2 capsules of 100 milligram (mg) each, orally, twice daily, continuously for 1 week. Total duration of treatment will be of 49 weeks. Efficacy will primarily be evaluated by percentage of participants showing 10 percent or higher response in SCIO Score. Participants' safety will be monitored throughout the study.
Subjects will receive BS006 every two weeks, and up to 4mL BS006 will be given. BS006 will be given intratumorally.
A prospective controlled randomized study was conducted on primary Immune thrombocytopenia patients. The study's main objective is to evaluate the efficacy and adverse events profile of the different therapeutic approaches during Immune thrombocytopenia. Upon the confirmation of the Immune thrombocytopenia diagnosis, all patients immediately initiated the High Dose-dexamethasone as a frontline therapy for Immune thrombocytopenia with a dose of 40 mg/m2 daily for 4 days/week in the first month for one cycle. Then, the recruited patients who fulfilled the inclusion criteria are randomly assigned into one of five groups. Among these patients, the control group received IV pulse (HD-DXM) therapy with 40 mg/m2 daily for 4 successive days in a 28-day cycle to complete the six cycles. The Prednisolone + Azathioprine group received 20 mg of Prednisolone three times daily and 1 mg/kg of oral Azathioprine once daily for two weeks, then tapering the Prednisolone dose through the subsequent weeks (6 weeks). While continuing treatment with Azathioprine for a total of six months. The Rituximab group received 500 mg/m2 intravenously of Rituximab once weekly for one month. The Eltrombopag group received 50 mg of Eltrombopag four hours before or after meals as oral daily doses for 6 months. The Romiplostim group received 3μg/kg sub-cutaneous injection of Romiplostim once a week for 6 months. The first evaluation date of confirmed ITP diagnosis was well-defined as the first index date (baseline). After that, every patient visited the investigational site as the protocol prescribes once weekly to assess and adjust the doses of study medications. The outcome measures were judged at baseline, at the end of treatment (6 months), and after an additional 6-month free treatment period.
Nimodipine, a calcium antagonist, exert beneficial neurovascular protective effects in clinic. Recently, Calcium channel blockers (CCBs) was reported to protect against liver fibrosis in mice, while the exact effects of Nimodipine on liver injury and hepatic fibrosis remain unclear. In this study, we assessed the effect of nimodipine in Thioacetamide (TAA)-induced liver fibrosis mouse model. Then, the collagen deposition and liver inflammation were assessed by HE straining. Also, the frequency and phenotype of NK cells, CD4+T and CD8+T cells and MDSC in liver and spleen were analyzed using flow cytometry. Furthermore, activation and apoptosis of primary Hepatic stellate cells (HSCs) and HSC line LX2 were detected using α-SMA staining and TUNEL assay, respectively. We found that nimodipine administration significantly attenuated liver inflammation and fibrosis. And the increase of the numbers of hepatic NK and NKT cells, a reversed CD4+/CD8+T ratio, and reduced the numbers of MDSC were observed after nimodipine treatment. Furthermore, nimodipine administration significantly decreased α-SMA expression in liver tissues, and increased TUNEL staining adjacent to hepatic stellate cells. Nimodipine also reduced the proliferation of LX2, and significantly promoted high level of apoptosis in vitro. Moreover, nimodipine downregulated Bcl-2 and Bcl-xl, simultaneously increased expression of JNK, p-JNK, and Caspase-3. Together, nimodipine mediated suppression of growth and fibrogenesis of HSCs may warrant its potential use in the treatment of liver fibrosis.
PURPOSE OF REVIEW: The aim of this study was to outline recent developments in calcium channel blocker (CCB) poisoning. The dihydropyridine CCB amlodipine is commonly prescribed in the United States, and amlodipine poisoning is increasing in frequency, presenting new challenges for clinicians because current paradigms of CCB poisoning management arose from literature on non-dihydropyridine agents.
RECENT FINDINGS: Amlodipine is now the most common CCB involved in poisoning. High-dose insulin is a potent inotrope and vasodilator; as such, it should be used cautiously, and typically in conjunction with vasopressors, as it theoretically may worsen vasodilation in amlodipine poisoning. High-dose insulin is best used when some degree of cardiogenic shock is suspected. Venoarterial extracorporeal membrane oxygenation utilization in CCB poisoning appears to be increasing, but high flow rates may be needed to combat amlodipine-induced vasoplegia. Intravenous lipid emulsion cannot be routinely recommended but may have a role in peri-arrest situations. Adjunct treatments such as angiotensin II, methylene blue, and hydroxocobalamin offer theoretical benefit but warrant further study.
SUMMARY: Amlodipine causes most cases of CCB poisoning and can induce both cardiogenic and distributive shock through multiple mechanisms. Clinicians should tailor treatment to suspected shock etiology, be aware of adjunct treatments for refractory shock, and consult an expert in poisoning.
The observed incidence of anti-drug antibodies (ADA) is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of ADA in the studies described below with the incidence of ADA in other studies, including those of setmelanotide or of other setmelanotide products.

In patients with POMC, PCSK1, or LEPR deficiency or in patients with BBS, there is insufficient information to characterize the ADA response to setmelanotide and the effects of ADA on pharmacokinetics, pharmacodynamics, safety, or effectiveness of setmelanotide products.

During the 1-year treatment period in Study 2 in patients with obesity due to LEPR deficiency [see Clinical Studies (14.1)], 3/7 (43%) of IMCIVREE-treated patients developed antibodies to endogenous alpha-melanocyte stimulating hormone (MSH). Of these 3 patients, 2 tested positive post-IMCIVREE treatment and 1 was positive pre-treatment. Because of the limited sample size, the effect of these antibodies on the pharmacokinetics, pharmacodynamics, safety, and/or effectiveness of setmelanotide products or consequences from these antibodies against endogenous alpha-MSH could not be determined. None of the IMCIVREE-treated patients with POMC-deficiency developed antibodies to alpha-MSH.
The investigators will select 30 patients with refractory focal epilepsy, 15 patients with refractory idiopathic generalized epilepsy and 15 patients with frequent tonic-clonic seizures, i.e. a group at increased risk for sudden unexpected death in epilepsy (SUDEP).
The present disclosure discloses an anti-Claudin 6 antibody and an antibody-drug conjugate. The present disclosure relates to an antigen sequence for preparing the Claudin 6 (CLDN6) antibody, a corresponding nucleotide sequence thereof, and a gene engineering vector, engineering bacterium or cell line for expressing the nucleotide sequence. A highly specific CLDN6 antibody may be produced by immunizing an animal with the antigenic polypeptide. Further, a corresponding monoclonal antibody may be obtained by preparing a hybridoma cell with a cell of the immunized animal. The anti-Claudin 6 antibody may be combined with a linking structure and a drug to form an antibody-drug conjugate. The antibody-drug conjugate may deliver the drug to a tumor cell having a positive expression of CLDN6 depending on the targeting effect of the CLDN6, thereby achieving the efficacy of specifically killing the tumor cell, which is of great significance for the treatment of the tumor.
Deficits in urologic function after spinal cord injury impact quality of life and consistently ranks as a top priority issue in the spinal cord injury population. Bladder dysfunction may manifest as detrusor hyperreflexia (bladder contractions at low volumes, causing incontinence and smooth muscle hypertrophy), detrusor-sphincter dyssynergia (uncoordinated bladder and external urethral sphincter contractions, causing inefficient emptying and smooth muscle hypertrophy), decreased compliance (unable to store urine under appropriately low pressures) and loss of continence, requiring lifelong management, maintenance, and health care visits. Current therapeutic approaches aim to manage both the storage and voiding phases of bladder function and include intermittent catheterization, pharmacologic and surgical interventions. While most of these strategies are necessary for urological maintenance post-injury they oftentimes are associated with side effects and therefore remain inadequate. Therapies addressing recovery of function are still needed. The use of spinal cord epidural stimulation is a promising alternative approach to addressing the primary phases of bladder dysfunction. Additionally, the effects of spinal cord epidural stimulation on bladder alone is not known as its use has been directed towards the locomotor system. Thus, the overall objective of this study is to perform functional mapping in order to identify the spinal cord epidural stimulation configurations (anode/cathode selection, amplitude, frequency and pulse width) at the lumbosacral level that can promote neural control of bladder storage (capacity) and bladder emptying (voiding efficiency) after spinal cord injury.
The introduction of lumen-apposing metal stents (LAMS) represented a great improvement in the EUS-guided transmural drainage of pancreatic fluid collections (PFCs). It is postulated safer than other types of stents due to the presence of bilateral anchoring flanges, designed to appose the stomach or duodenum to the PFC wall minimizing the risk of perforation or peritoneal leakage. In addition, the larger lumen diameter facilitates the drainage of PFC, specially the walled-off pancreatic necrosis (WOPN). However, secondary adverse effects such as infection due to complete or partial stent obstruction, migration, bleeding or buried LAMS syndrome have also been related . The placement of a coaxial double pigtail plastic within the LAMS has been reported beneficial in order to avoid external migration or the lumen obstruction and to the prevention of bleeding and other adverse events. The aim of this study was to evaluate the efficacy and safety of LAMS with and without a coaxial double pigtail plastic stent in the EUS-guided transmural drainage of PFCs.
The tumor microenvironment is affected by reactive oxygen species and has been suggested to have an important role in ovarian cancer (OC) tumorigenesis. The role of glutathione transferases (GSTs) in the maintenance of redox balance is considered as an important contributing factor in cancer, including OC. Furthermore, GSTs are mostly encoded by highly polymorphic genes, which further highlights their potential role in OC, known to originate from accumulated genetic changes. Since the potential relevance of genetic variations in omega-class GSTs (GSTO1 and GSTO2), with somewhat different activities such as thioltransferase and dehydroascorbate reductase activity, has not been clarified as yet in terms of susceptibility to OC, we aimed to investigate whether the presence of different GSTO1 and GSTO2 genetic variants, individually or combined, might represent determinants of risk for OC development. Genotyping was performed in 110 OC patients and 129 matched controls using a PCR-based assay for genotyping single nucleotide polymorphisms. The results of our study show that homozygous carriers of the GSTO2 variant G allele are at an increased risk of OC development in comparison to the carriers of the referent genotype (OR1 = 2.16, 95% CI: 0.88-5.26, p = 0.08; OR2 = 2.49, 95% CI: 0.93-6.61, p = 0.06). Furthermore, individuals with GST omega haplotype H2, meaning the concomitant presence of the GSTO1*A and GSTO2*G alleles, are more susceptible to OC development, while carriers of the H4 (*A*A) haplotype exhibited lower risk of OC when crude and adjusted haplotype analysis was performed (OR1 = 0.29; 95% CI: 0.12-0.70; p = 0.007 and OR2 = 0.27; 95% CI: 0.11-0.67; p = 0.0054). Overall, our results suggest that GSTO locus variants may confer OC risk.
Midwifery education consists of two parts, theoretical and clinical, which complement each other. Educators in the field of midwifery should strengthen students' skills before going to the clinic by following innovative training techniques. In this context, it is recommended that the simulation supported midwifery education model be used, disseminated and included in the curriculum of midwifery departments, as it contributes to students.To investigate the effect of the exercise program with the 'Empathy Dress' applied to midwifery students on the Levels of physical discomfort, empathy and compassionate love in the midwifery department of Amasya University. A total of 62 midwifery student (31 experimental, 31 control) are planned to be included in the study. Data will be collected with the "Student Information Form", "The Toronto Empathy Questionnaire- TEQ", "Evaluation Scale for Physical Discomfort", and "The Compassionate Love Scale". In the study, an exercise program that includes a total of eight sessions (two months) of 'Empathy Dress' and some exercises (stairs going up and down, sitting up, putting on trousers, tying shoes, etc.), every week and 20 minutes per week to the midwifery students in the experimental group, by the researcher. The expected result of the study is to determine whether the exercise program with the 'Empathy Dress' is an effective intervention in increasing the empathy and compassionate love levels in midwifery students. In addition, the effect of the 'Empathy Dress' and exercise program on the physical discomfort levels of midwifery students is investigated. It is thought that the results of the study will improve the empathy and sensitive love levels of midwifery students and increase the quality of midwifery care offered.
1. Antidepressant medicines may increase suicidal thoughts or actions in some children, teenagers, and young adults within the first few months of treatment.
  2. Depression and other serious mental illnesses are the most important causes of suicidal thoughts and actions. Some people may have a particularly high risk of having suicidal thoughts or actions. These include people who have (or have a family history of) bipolar illness (also called manic-depressive illness) or suicidal thoughts or actions.
A fixative composition for artificial dentures comprises one or more ethylene oxide homopolymers of molecular weight between 500,000 and 5,000,000, and one or more of the following additives:- natural or synthetic gums, flavouring agents, extenders, plasticizers, buffers, flow promoters, pigments and dyes.  The proportion of polymer may be as low as 0,5% by weight but the examples give proportions of from 99,8% to 9,5%.  Specified additives are Gum Karaya, carboxymethyl cellulose, petrolatum, paraffin wax, sodium borate, aluminium hydrate, diatomaceous earth, magnesium oxide, isopropyl palmitate, hexachlorophene, dyes and flavours, e.g. peppermint, spearmint, methyl salicylate and clove oil.  The compositions may be in the form of powders, films or pastes.  As paste carriers, fats, fatty acids and their esters may be used instead of petrolatum.ALSO:A denture fixative comprises at least 0,5% by weight of one or more ethylene oxide homopolymers of molecular weight between 500,000 and 5,000,000, and one or more of the following additives:- natural or synthetic gums, flavouring agents, extenders, plasticisers, buffers, flow promoters, pigments and dyes.  In the examples, the proportions of polymer range from 9,5% to 99,8%.  Specified additives are Gum Karaya, carboxymethyl cellulose, petrolatum, paraffin wax, sodium borate, aluminium hydrate, diatomaceous earth, magnesium oxide, isopropyl palmitate, hexachlorophene, dyes and flavours, e.g. peppermint, spearmint, methyl salicylate and clove oil.  The compositions may be in the form of powders, films or pastes.  As paste carriers, fats, fatty acids and their esters may be used instead of petrolatum.
Brentuximab vedotin (BV) has obtained approval for the therapeutic management of classical Hodgkin lymphoma as well as systemic anaplastic large cell lymphoma. Given the inherent constraints of conventional clinical trials, the correlation between BV and cardiac adverse events (AEs) remains enigmatic. The objective of this investigation is to comprehensively assess cardiac AEs attributed to BV by employing advanced data mining techniques, utilizing the FDA Adverse Event Reporting System (FAERS). The indices for the assessment of disproportionality encompass the reporting odds ratio (ROR), the proportional reporting ratio, the information component, and the empirical Bayesian geometric mean. Employing these sophisticated metrics, we gauged the extent of disproportionate occurrences. The dataset was sourced from the FAERS from the first quarter of 2012 to first quarter of 2023, facilitating a comprehensive analysis of the potential correlation between BV and cardiac AEs. This scrutiny encompassed a comparative analysis of both cardiac and non-cardiac AEs. A total of 495 cases of BV's cardiac AEs were discerned, with the identification of 31 preferred terms (PTs). Among these, 8 PTs emerged as conspicuous signals of cardiac AEs, notably encompassing ventricular hypokinesia (ROR 7.59), tachyarrhythmia (ROR 7.06), sinus tachycardia (ROR 6.18), cardiopulmonary failure (ROR 4.44), pericardial effusion (ROR 4.32), acute coronary syndrome (ROR 4.02), cardiomyopathy (ROR 3.30), and tachycardia (ROR 2.76). The manifestation of severe outcomes demonstrates a discernible correlation with the cardiac AEs (P < 0.001). Our investigation furnishes invaluable insights for healthcare practitioners to proactively mitigate the incidence of BV-associated cardiac AEs.
A method and system to “pump” radiation therapy (RT) images and associated patient information on an Image Guided Radiation Therapy (IGRT) system to a Record and Verify (R&V) system via a standard DICOM connection to allow remote image viewing. Targeted image files in IGRT systems are searched for and transferred automatically. The user identifies the “inlet,” i.e. the source from which the image files are searched, and the “outlet,” i.e., the DICOM server to which the “pumped” imaged are directed. The images can be sent in their original form or fused. The “input” source is scanned periodically at a user-determined time interval. In order not to send the same image multiple time, a time filter skips images generated before a user-selected time and date.